Four-year entecavir therapy reduces hepatocellular carcinoma, cirrhotic events and mortality in chronic hepatitis B patients

TUNG-HUNG SUHu T.-H.Chen C.-Y.Huang Y.-H.Chuang W.-L.Lin C.-C.Wang C.-C.Su W.-W.Chen M.-Y.Peng C.-Y.Chien R.-N.YI-WEN HUANGWang H.-Y.Lin C.-L.Yang S.-S.Chen T.-M.Mo L.-R.SHIH-JER HSUTseng K.-C.Hsieh T.-Y.Suk F.-M.Hu C.-T.Bair M.-J.Liang C.-C.Lei Y.-C.TAI-CHUNG TSENGCHI-LING CHENJIA-HORNG KAOthe C-TEAM study groupthe Taiwan Liver Diseases Consortium2021-03-092021-03-0920161478-3223https://www.scopus.com/inward/record.uri?eid=2-s2.0-84994810216&doi=10.1111%2fliv.13253&partnerID=40&md5=b190e81250f88c50adfbc737a76cef65https://scholars.lib.ntu.edu.tw/handle/123456789/551101[SDGs]SDG3Four-year entecavir therapy reduces hepatocellular carcinoma, cirrhotic events and mortality in chronic hepatitis B patientsjournal article10.1111/liv.13253276341342-s2.0-84994810216